XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Accounts Receivable
 3 Months Ended
Mar. 31, 2025
Receivables [Abstract]  
Accounts Receivable Accounts Receivable
The Company’s accounts receivable consists primarily of amounts due from third-party payors and patients. See Note 2 for a summary of the Company’s policies relating to accounts receivable and allowance for credit losses.
Accounts Receivable as of March 31, 2025 and December 31, 2024 consist of the following:
(in thousands)March 31, 2025December 31, 2024
Oral drug accounts receivable (Dispensary)$7,623 $6,371 
Capitated accounts receivable (Patient Services)3,883 3,695
FFS accounts receivable (Patient Services)28,593 26,532
Clinical trials accounts receivable1,830 1,863
Other trade receivables7,391 9,874
Total$49,320 $48,335 
No allowance for credit losses was recorded as of March 31, 2025 and December 31, 2024.
As of January 1, 2024, the accounts receivable balance amounted to $42,360.
During the three months ended March 31, 2025 and 2024, the Company had no net bad debt recoveries and bad debt expense. Credit losses are a result of accounts receivable on completed contracts that were deemed uncollectible during the period due to delayed collection efforts.